79 recruiting, 44 active not recruiting, 32 completed, 20 not yet recruiting. 150 Phase 2, 77 Phase 1, 17 Phase 3, 2 Early Phase 1, 1 Not applicable.
Follow cemiplimab: new trials by email Literature Review of cemiplimab trials Research Report on cemiplimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck Cemiplimab, Fianlimab, Carboplatin - Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | University of Chicago | 90 | 2027-02-07 | 2026-01-20 |
| Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer Cemiplimab, Zanzalintinib - Anaplastic Thyroid Cancer | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 12 | 2027-01-31 | 2026-10-14 |
| Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1 Cemiplimab, Adjuvant chemotherapy - Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Henry Ford Health System | 33 | 2027-01-01 | 2026-07-15 |
| A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab), Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments), Ablative Hypofractionated Radiotherapy - Non-Small Cell Lung Cancer, Metastatic Lung Cancer | Phase 2 | Recruiting | University of Chicago | 39 | 2026-12-12 | 2026-06-16 |
| Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma Actinium Ac 225 Lintuzumab, Biospecimen Collection, Cemiplimab - Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 30 | 2026-12-04 | 2026-06-12 |
| Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma Fianlimab, Cemiplimab - Melanoma (Skin) | Phase 2 | Not yet recruiting | University of California, Irvine | 35 | 2026-12-01 | 2026-09-11 |
| Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma Cemiplimab, Prednisone, Sirolimus - Kidney Transplant Recipient, Cutaneous Squamous Cell Carcinoma (CSCC) | Phase 2 | Not yet recruiting | Washington University School of Medicine | 22 | 2026-11-30 | 2026-10-15 |
| Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas NeuroBlate® Laser Ablation Laser Interstitial Thermal Therapy, Cemiplimab, Chemotherapy - Glioblastoma, Glioblastoma, IDH-wildtype | Phase 2 | Not yet recruiting | Washington University School of Medicine | 99 | 2026-11-30 | 2026-10-20 |
| Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer Cemiplimab, Carboplatin + Pemetrexed/Paclitaxel, Cisplatin - Non-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Medical University of South Carolina | 38 | 2026-11-01 | 2026-07-22 |
| RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer Cemiplimab 350 mg IV - Non Small Cell Lung Cancer, Immunotherapy | Phase 2 | Not yet recruiting | The Netherlands Cancer Institute | 30 | 2026-11-01 | 2026-10-05 |
| Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma Cetuximab, Cemiplimab - Locally Advanced Cutaneous Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Melanoma and Skin Cancer Trials Limited | 27 | 2026-10-30 | 2026-10-07 |
| A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC) Cemiplimab, Vidutolimod, Fianlimab - Locally Advanced Basal Cell Carcinoma | Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 135 | 2026-10-15 | 2026-09-09 |
| Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] - Colon Cancer | Phase 2 | Not yet recruiting | John Strickler, M.D. | 24 | 2026-10-01 | 2026-08-27 |
| Cemiplimab and Quad Shot Radiation for Cutaneous Squamous Cell Carcinoma in the Head and Neck Cemiplimab, Radiation Therapy - Cutaneous Squamous Cell Carcinoma | Early Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 25 | 2026-09-01 | 2026-10-13 |
| A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma Cemiplimab, Fianlimab - Nasopharyngeal Carcinoma, Nasopharyngeal Cancer | Phase 1 | Not yet recruiting | Memorial Sloan Kettering Cancer Center | 60 | 2026-09-01 | 2026-08-11 |
| Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial Cemiplimab - Nsclc, NSCLC Stage II | Phase 2 | Not yet recruiting | University of Maryland, Baltimore | 30 | 2026-09-01 | 2026-08-07 |
| A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer Stereotactic body radiotherapy, Cemiplimab, Cemiplimab and Fianlimab - Bladder Urothelial Carcinoma | Phase 2 | Withdrawn | Memorial Sloan Kettering Cancer Center | 2026-09-01 | 2026-09-03 | |
| PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma Cemiplimab, Lpilimumab, Fianlimab - Melanoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 20 | 2026-09-01 | 2026-04-06 |
| Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma Biopsy Procedure, Biospecimen Collection, Carboplatin - Sinonasal Squamous Cell Carcinoma, Stage III Sinonasal Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 108 | 2026-09-01 | 2026-10-05 |
| A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma Cemiplimab, Cemiplimab+Fianlimab Fixed Dose Combination (FDC) - High-Grade Glioma (HGG), Posterior Fossa-A Ependymoma | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 120 | 2026-08-31 | 2026-05-05 |
Showing 20 of 217. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (53) · Melanoma (23) · Neoplasm Metastasis (19) · Neoplasms (19) · Squamous Cell Carcinoma of Head and Neck (17) · Skin Neoplasms (14) · Lung Neoplasms (13) · Head and Neck Neoplasms (10) · Recurrence (10) · Carcinoma, Basal Cell (9) · Carcinoma, Renal Cell (9) · Carcinoma, Squamous Cell (9) · Breast Neoplasms (8) · Colorectal Neoplasms (8) · Ovarian Neoplasms (8)
Regeneron Pharmaceuticals (55) · M.D. Anderson Cancer Center (12) · Sanofi (8) · National Cancer Institute (NCI) (7) · Memorial Sloan Kettering Cancer Center (6) · H. Lee Moffitt Cancer Center and Research Institute (4) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4) · BioNTech SE (3) · Columbia University (3) · Mayo Clinic (3) · University of Chicago (3) · Biohaven Therapeutics Ltd. (2) · City of Hope Medical Center (2) · Dana-Farber Cancer Institute (2) · Duke University (2)
United States (161) · Spain (44) · France (36) · Australia (34) · Italy (34) · Germany (26) · South Korea (21) · Canada (20) · Belgium (18) · United Kingdom (18) · Brazil (17) · Netherlands (17) · Poland (16) · Taiwan (15) · Turkey (Türkiye) (14)
Eric Christenson, MD (2) · Gino K In, MD (2) · Ralf Gutzmer, Prof. Dr. med. (2) · Adam Dicker, MD (1) · Adanma Ayanambakkam, MD (1) · Ahmad Tarhini, MD, PHD (1) · Aixa E Soyano Muller, MD (1) · Alexander Z Wei, MD (1) · Alfredo Berruti, Prof, MD (1) · Alice Bexon, MD (1) · Alison O'Neill, MD (1)
PMID 29863979, PMID 32554615, PMID 35175355, PMID 21796368, PMID 22198468, PMID 22623692, PMID 22649152, PMID 27406346, PMID 27406347, PMID 27879972, PMID 28851423, PMID 29950349, PMID 31585957, PMID 31951149, PMID 31952975, PMID 32031889, PMID 32053137, PMID 32450725, PMID 32701140, PMID 33146741, PMID 33224628, PMID 33477979, PMID 33581821, PMID 33768419, PMID 33831732, PMID 33929394, PMID 33942954, PMID 34000246, PMID 34187851, PMID 34413166, PMID 34529000, PMID 34741021, PMID 34850166, PMID 35058326, PMID 35065058, PMID 35139273, PMID 35605659, PMID 35623341, PMID 35922251, PMID 35993306, PMID 36008722, PMID 36069821, PMID 36094839, PMID 36308296, PMID 36456573, PMID 36821617, PMID 36898933, PMID 37001859, PMID 37029329, PMID 37315579
2023 (12), 2017 (8), 2025 (7), 2016 (6), 2019 (4), 2018 (3), 2015 (2), P30CA014089 (2), P30CA033572 (2), P30CA138292 (2), P50CA186781 (2), R01CA262613 (2), U10CA180868 (2), UM1CA186691 (2), P01CA247886 (1)